Skip to main content
. 2015 Jan;36(1):70–76. doi: 10.3174/ajnr.A4065

Fig 4.

Fig 4.

Kaplan-Meier curves showing the PFS for patients with low-grade gliomas. A, No significant difference was observed between patients with wild-type p53 tumors and those with mutant p53 tumors (log-rank, P = .2994). B, A statistically significant difference in PFS was observed between patients with tumors in VLSM-identified regions and patients with tumors located outside VLSM-identified regions (log-rank, P = .0269). C, Among patients with tumors located in VLSM-identified regions, a trend toward a difference in PFS was observed between patients with wild-type p53 tumors and those with mutant p53 tumors (log-rank, P = .1032). D, Among patients with mutant p53 tumors, a significantly worse PFS was observed in patients with tumors located in VLSM-identified regions compared with patients with tumors outside these regions (log-rank, P = .0088).